D.2.d J-and-A-Other-Than-Full-and-Open Redacted.pdf

This document provides a justification and approval for a modification to contract number 75D30120C08170 awarded by the Centers for Disease Control and Prevention to Vitalant on February 22, 2022. The contract supports the National SARS-CoV-2 Seroincidence Studies in Blood Donors by expanding longitudinal participant recruitment to approximately 130,000 blood donors. This will provide data on the stability of potentially protective antibody responses and refine the analysis of serosurvey results to account for waning seroreactivity. Task 2 of the contract is modified to accomplish this expanded effort through additional repeat testing of participants averaging 3 to 5 times per year. The period of performance is extended by one year from May 11, 2022 to May 11, 2023. The justification cites Vitalant as the only responsible source capable of providing this work due to existing partnerships, access to blood donor pools, and 20 months of collected testing and data through previous contract performance.